Company Overview
About Viridian Therapeutics
Viridian Therapeutics is a Greenwood Village, Colorado-based clinical-stage biotechnology company — backed by Y Combinator (W20) and publicly traded on NASDAQ (VRDN) — developing FcRn inhibitor therapies for thyroid eye disease (TED) and other serious rare diseases driven by IgG autoantibodies. Maintaining $636.6 million in cash and short-term investments as of March 2025 (sufficient to fund operations into the second half of 2027), Viridian is advancing veligrotug (subcutaneous FcRn inhibitor, BLA submission expected H2 2025 for TED, MAA to EMA expected H1 2026), VRDN-003 (topline clinical data expected H1 2026), and VRDN-006 (proof-of-concept data expected Q3 2025), with $86.6 million in R&D expenses in Q2 2025 reflecting accelerated clinical development investment.
Business Model & Competitive Advantage
Viridian's FcRn inhibitor platform addresses the treatment gap in thyroid eye disease and IgG-mediated autoimmune conditions: thyroid eye disease (affecting 50,000+ new US patients annually, associated with Graves' hyperthyroidism) causes the immune system to produce IgG antibodies that attack the thyroid-stimulating hormone receptor in orbital tissue — causing proptosis (eye protrusion), diplopia (double vision), and orbital inflammation that significantly impairs quality of life. FcRn inhibitors (blocking the neonatal Fc receptor that recycles IgG antibodies, thereby reducing circulating IgG levels and the autoantibody burden driving the disease) represent a mechanistically differentiated approach from the currently approved standard (teprotumumab/Tepezza, which targets IGF-1R). Viridian's subcutaneous formulation (self-injectable) versus teprotumumab's IV infusion provides meaningful patient convenience differentiation if clinical efficacy is comparable.
Competitive Landscape 2025–2026
In 2025, Viridian competes in the thyroid eye disease therapeutics and rare autoimmune market with Amgen/Horizon Therapeutics (NASDAQ: AMGN, Tepezza for TED, $1.9B 2023 revenue), Immunovant (NASDAQ: IMVT, FcRn inhibitor platform, $400M raised), and Argenx (NASDAQ: ARGX, efgartigimod FcRn inhibitor, $1.7B revenue) for TED and IgG-autoantibody disease FcRn inhibitor therapy market positioning. The NASDAQ listing and $636.6M cash position reflect biotech market financing strength. Y Combinator W20 backing (unusual for a clinical-stage biotech) provides organizational credibility and investor network connectivity. The 2025 strategy focuses on the veligrotug BLA submission and FDA review process, enrolling the VRDN-003 Phase 3 program, and positioning Viridian as a multi-asset rare autoimmune company beyond TED with the FcRn platform.
Recent Activity
View all →Key Differentiators
Emerging Innovator
Viridian Therapeutics is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Viridian Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Viridian Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Viridian Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Viridian Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →